Tirzepatide is a single molecule sold under two brand names and mixed by compounding pharmacies under neither, and its price swings wildly depending on which of those doors you walk through. As branded Zepbound, as branded Mounjaro, or as compounded tirzepatide, it can cost anywhere from under a hundred dollars to well over a thousand a month. This page is the side-by-side across all of those forms — the map, not the sales pitch. Figures below are widely reported U.S. approximations as of mid-2026; they move often and should be treated as ballpark, not quotes. For the deep dive on any one route, we link the dedicated guides as we go.
The one-molecule, three-forms problem
Tirzepatide is a dual GIP/GLP-1 receptor agonist, and it is the same active drug whether the label says Zepbound or Mounjaro. The two brands differ in their approved use, not their chemistry: Zepbound is FDA-approved for chronic weight management, while Mounjaro is approved for type 2 diabetes. Because insurers decide coverage by indication, that labeling split is exactly what makes the price so route-dependent — the same molecule can be covered under one brand and denied under the other on the same plan. If you are also weighing tirzepatide against the semaglutide drugs (Wegovy, Ozempic), the efficacy and price comparison is laid out in tirzepatide vs semaglutide.
Cost by form: the side-by-side
Here is the whole market in one view. Each row is the same drug; the difference is the door. Treat every number as an approximation that changes with dose, plan, pharmacy and month.
| Route | Brand / form | Approved for | Approx. monthly cost |
|---|---|---|---|
| Self-pay vials (LillyDirect) | Zepbound (single-dose vials) | Weight management | ~$349–$499 by dose |
| List / WAC (before insurance) | Mounjaro (pens) | Type 2 diabetes | ~$1,080+ |
| List / WAC (before insurance) | Zepbound (pens) | Weight management | ~$1,086 |
| Commercial insurance + savings card | Zepbound or Mounjaro | Per plan's covered indication | as low as ~$25 copay |
| Compounded (telehealth) | Compounded tirzepatide | Not FDA-approved | ~$99–$329 |
Route 1 — Zepbound self-pay vials (~$349–$499/mo)
For people paying cash for the weight-management indication, the lowest-cost route to branded, FDA-approved tirzepatide is Lilly’s own self-pay channel: single-dose vials of Zepbound sold through LillyDirect, priced by dose as a 4-week supply. Widely reported figures put this in the neighborhood of $349 to $499 a month depending on the strength and on refilling within the program’s window; miss the refill timing and the higher doses can revert upward.[1] These are approximate and change periodically, so confirm the live number on Lilly’s page before budgeting. We keep the brand-specific breakdown — every tier, the refill catch, and the savings-card mechanics — in the dedicated Zepbound cost guide.
Route 2 — Mounjaro list price ($1,000+/mo before insurance)
Mounjaro, the diabetes brand of tirzepatide, carries a list price (wholesale acquisition cost) widely reported at more than $1,000 a month for a 28-day supply — in the same range as Zepbound’s roughly $1,086 sticker.[1] As with Zepbound, that list price is what almost no one with coverage actually pays; it is the number your insurer negotiates down from. Because Mounjaro is a diabetes drug, commercial plans are generally more willing to cover it than a weight-loss brand, which is often the practical reason people end up with a Mounjaro prescription rather than Zepbound. The routes to obtaining it — and how coverage is decided — are in how to get Mounjaro.
Route 3 — commercial insurance, prior authorization, and the savings card
For most people with commercial insurance, the real out-of-pocket cost is not set by any sticker at all — it is set by three things: whether your plan covers tirzepatide for your indication, whether you clear prior authorization (and sometimes step therapy), and whether you qualify for the manufacturer savings card. When all three line up, the copay can fall to as little as ~$25/month, subject to monthly and annual caps.[1] Two limits are worth flagging up front: the savings card is for commercial insurance only — Medicare, Medicaid, the VA, DOD and TRICARE are excluded by its terms — and coverage for weight-loss indications has historically been the harder sell. The mechanics of formularies and prior authorization are where your price is really decided.
Route 4 — compounded tirzepatide (~$99–$329/mo), and why it’s cheaper
Search for a bargain and you will hit telehealth clinics advertising compounded tirzepatide well below the branded self-pay price — commonly in the ~$99 to $329 a month range, sometimes bundled into a subscription. It looks cheaper for concrete reasons: compounded drugs skip the branded manufacturer’s pricing, are mixed by a pharmacy rather than produced under Lilly’s process, and — critically — are not FDA-approved. No compounded version has been reviewed for safety, efficacy, or manufacturing quality the way the branded product has. That missing review is, in effect, the discount.
It is also a narrowing door. During the 2023–24 shortage, compounding tirzepatide was broadly permitted, but the FDA declared the tirzepatide shortage resolved in October 2024, which ended the broad compounding exceptions. In 2026 the agency went further, proposing to exclude tirzepatide (along with semaglutide and liraglutide) from the list of bulk substances that 503B outsourcing facilities may compound.[2] The practical takeaway: a cheap compounded offer in 2026 is operating in a shrinking, legally contested space, not a settled discount channel. If price is your main concern, the honest tradeoff — and the cheapest legitimate routes — are mapped in the cheapest ways to get tirzepatide.
Why cost is a clinical question, not just a budgeting one
It is worth remembering what you are paying for. In SURMOUNT-1, the pivotal obesity trial, tirzepatide produced mean weight reductions of roughly 15% to 21% of body weight at the higher doses over 72 weeks — results that put it among the most effective pharmacological options for weight management.[3]But that benefit only holds while treatment continues. Real-world studies of why people stop GLP-1 and dual-agonist therapy find that cost and loss of coverage are among the leading reasons for discontinuation, alongside side effects.[4] Because stopping typically reverses much of the weight loss, an affordability gap functions as a treatment failure. The cheapest route you can sustain usually beats a slightly cheaper one you cannot.
The honest bottom line
There is no single “price of tirzepatide.” If you have commercial insurance that covers it, prior authorization plus the savings card likely puts you near $25 a month. If you are paying cash for weight management, Zepbound self-pay vials at roughly $349–$499 by dose are the lowest-cost approved option. Mounjaro’s $1,000-plus list price is a pre-insurance sticker, not a bill most covered patients pay. Compounded tirzepatide is cheaper on paper at ~$99–$329, but it is not FDA-approved and its legal pathway has narrowed. Every figure here moves, so verify the current number on the manufacturer’s own pages before you commit. For the route-by-route detail, follow the Zepbound cost and cheapest-tirzepatide guides.